Monitor the stockholder meeting scheduled by July 21, 2026, which would trigger exercisability of Class J warrants and enable additional selling. Watch for open-market sales by major holders like Armistice Capital and Orca Capital, who collectively hold over 56% of pre-offering shares. The stock's proximity to the NYSE American's $0.10 low-price delisting threshold adds downside risk.
Executive Summary
AIM ImmunoTech filed a new S-1 registration statement to register 13,077,089 shares of common stock for resale by selling stockholders, consisting of PIPE shares, Pre-Funded Warrants, Class J Warrants, and placement agent warrants from the June 2026 offering. The company receives no proceeds from this resale, and the filing adds to massive existing warrant overhang (over 37M additional shares from prior warrants), creating significant dilution risk for a company with a ~$11M market cap and a going-concern opinion from its auditors.
Key Facts
- Registers 13,077,089 shares for resale by selling stockholders from the June 2026 offering
- Company receives no proceeds from resale; would get ~$5.5M only if all warrants exercised for cash
- Current shares outstanding: 27,724,245; after full warrant exercise: 40,801,334 (47% dilution)
- Stock closed at $0.40 on June 17, 2026, well below the Class J warrant exercise price of $0.5189
- Auditor's report contains a going-concern explanatory paragraph
- Class J warrants require stockholder approval (meeting by July 21, 2026) before exercisable
- Combined with prior EFFECT filing (June 17), total shares registered for resale across both filings exceeds 44M
- Top holders include Armistice Capital (27.59% pre-offering), Orca Capital (15.21%), Intracoastal Capital (13.54%)
Financial Impact
Potential selling pressure of ~$5.2M at current $0.40 price from the 13M shares registered; if all outstanding warrants across all tranches are exercised, total shares could exceed 80M, representing ~3x dilution from current float
Risk Factors
- Massive dilution from multiple warrant tranches (Class H, I, J and others) totaling over 37M additional shares
- NYSE American delisting risk with stock at $0.40 and low-price threshold of $0.10
- Going-concern qualification from independent auditor
- Penny stock designation if delisted, reducing liquidity
- Company has no FDA-approved products in the US; Ampligen only approved in Argentina for CFS
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1 Filing (Primary) | 0001493152-26-029193 |
| Exhibit: ex107.htm | 0001493152-26-029193 |
| Exhibit: ex5-1.htm | 0001493152-26-029193 |
| Exhibit: ex23-1.htm | 0001493152-26-029193 |
| Document: 0001493152-26-029193-index-headers.html | 0001493152-26-029193 |
| Document: 0001493152-26-029193-index.html | 0001493152-26-029193 |
| Document: 0001493152-26-029193.txt | 0001493152-26-029193 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 30, 2026 25d ago | DEF 14A | $0.1877 | awaiting T+20 | — | $0.1600 (−14.76%) |
Sep 22, 2026 4w ago | Press Release | $0.2156 $0.1662 | ▼ −22.91% | ▼ −22.35% | $0.1600 (−25.79%) |
Sep 14, 2026 5w ago | 8-K | $0.2100 | awaiting T+20 | — | $0.1600 (+23.81%) |
Aug 11, 2026 10w ago | 8-K | $0.2500 $0.2332 | ▼ −6.72% | ▼ −5.66% | $0.1600 (−36.00%) |
Aug 10, 2026 10w ago | 8-K | $0.2630 | awaiting T+20 | — | $0.1600 (+39.16%) |
Aug 10, 2026 10w ago | Press Release | $0.2630 | awaiting T+20 | — | $0.1600 (+39.16%) |
Aug 5, 2026 11w ago | 8-K | $0.2800 $0.2346 | ▼ −16.21% | ▼ −15.61% | $0.1600 (−42.86%) |
Aug 3, 2026 11w ago | Press Release | $0.2600 $0.2260 | ▼ −13.08% | ▼ −14.31% | $0.1600 (−38.46%) |
Jun 24, 2026 17w ago | EFFECT | $0.3740 $0.2534 | ▲ +32.25% | ▲ +34.18% | $0.1600 (+57.22%) |
Jun 18, 2026 18w ago | S-1 | $0.3799 $0.2730 | ▲ +28.14% | ▲ +28.67% | $0.1600 (+57.88%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers